127 related articles for article (PubMed ID: 12553478)
1. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy.
Venturi G; Romano L; Carli T; Corsi P; Pippi L; Valensin PE; Zazzi M
Antivir Ther; 2002 Dec; 7(4):245-50. PubMed ID: 12553478
[TBL] [Abstract][Full Text] [Related]
2. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
[TBL] [Abstract][Full Text] [Related]
5. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
[TBL] [Abstract][Full Text] [Related]
6. Analysis of a long-term discrepancy in drug-targeted genes in plasma HIV-1 RNA and PBMC HIV-1 DNA in the same patient.
Usuku S; Noguchi Y; Sakamoto M; Adachi T; Sagara H; Sudo K; Nishizawa M; Kondo M; Tochikubo O; Imai M
Jpn J Infect Dis; 2006 Apr; 59(2):122-5. PubMed ID: 16632914
[TBL] [Abstract][Full Text] [Related]
7. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
8. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
[TBL] [Abstract][Full Text] [Related]
9. Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART.
Monno L; Punzi G; Scarabaggio T; Saracino A; Brindicci G; Fiore JR; Iambrenghi OC; Di Stefano M; Pastore G; Angarano G
J Med Virol; 2003 May; 70(1):1-9. PubMed ID: 12629636
[TBL] [Abstract][Full Text] [Related]
10. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.
Pellegrin I; Thiébaut R; Blanco P; Viallard JF; Schrive MH; Merel P; Chêne G; Fleury H; Moreau JF; Pellegrin JL
J Med Virol; 2005 Oct; 77(2):164-72. PubMed ID: 16121362
[TBL] [Abstract][Full Text] [Related]
11. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
[TBL] [Abstract][Full Text] [Related]
12. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
[TBL] [Abstract][Full Text] [Related]
13. Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management.
Bon I; Alessandrini F; Borderi M; Gorini R; Re MC
New Microbiol; 2007 Jul; 30(3):313-7. PubMed ID: 17802917
[TBL] [Abstract][Full Text] [Related]
14. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
[TBL] [Abstract][Full Text] [Related]
15. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy.
Devereux HL; Youle M; Johnson MA; Loveday C
AIDS; 1999 Dec; 13(18):F123-7. PubMed ID: 10630517
[TBL] [Abstract][Full Text] [Related]
16. Different resistance mutations can be detected simultaneously in the blood and the lung of HIV-1 infected individuals on antiretroviral therapy.
White NC; Israel-Biet D; Coker RJ; Mitchell DM; Weber JN; Clarke JR
J Med Virol; 2004 Mar; 72(3):352-7. PubMed ID: 14748057
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cell-free and cell-associated peripheral blood human immunodeficiency virus type 1 RNA response to antiretroviral therapy.
Romano L; Venturi G; Catucci M; De Milito A; Valensin PE; Zazzi M
J Infect Dis; 1999 Feb; 179(2):361-6. PubMed ID: 9878019
[TBL] [Abstract][Full Text] [Related]
18. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
19. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
20. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]